Applied DNA Sciences, Inc. (APDN)
NASDAQ: APDN · Real-Time Price · USD
0.191
+0.001 (0.74%)
At close: Jan 17, 2025, 4:00 PM
0.189
-0.003 (-1.46%)
Pre-market: Jan 21, 2025, 7:00 AM EST
Applied DNA Sciences Revenue
In the fiscal year ending September 30, 2024, Applied DNA Sciences had annual revenue of $3.43M, down -74.33%. Applied DNA Sciences had revenue of $813.11K in the quarter ending September 30, 2024, with 4.28% growth.
Revenue (ttm)
$3.43M
Revenue Growth
-74.33%
P/S Ratio
0.22
Revenue / Employee
$71,488
Employees
48
Market Cap
10.01M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 3.43M | -9.94M | -74.33% |
Sep 30, 2023 | 13.37M | -4.80M | -26.43% |
Sep 30, 2022 | 18.17M | 9.14M | 101.25% |
Sep 30, 2021 | 9.03M | 7.10M | 367.40% |
Sep 30, 2020 | 1.93M | -3.46M | -64.16% |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
APDN News
- 10 days ago - Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates - Accesswire
- 12 days ago - Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter - Accesswire
- 4 weeks ago - Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA - Accesswire
- 4 weeks ago - Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines - Accesswire
- 5 weeks ago - Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out - Accesswire
- 2 months ago - Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement - Accesswire
- 3 months ago - Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16 - Accesswire
- 4 months ago - Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement - Accesswire